NFE2L2 and neoplasm: Our data, for the first time, identified the modulatory function that ZNF521 exerts on the NRF2-NOTCH axis in this tumor model, and whose expression could be used to select hOC patients potentially responsive to treatments with NRF2 or NOTCH inhibitors [80,81].